Compare INSM & DEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INSM | DEO |
|---|---|---|
| Founded | 1988 | 1886 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Beverages (Production/Distribution) |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 47.6B |
| IPO Year | 2000 | N/A |
| Metric | INSM | DEO |
|---|---|---|
| Price | $176.09 | $86.99 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 21 | 2 |
| Target Price | ★ $185.84 | $109.00 |
| AVG Volume (30 Days) | ★ 3.8M | 1.7M |
| Earning Date | 02-19-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 4.72% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.06 |
| Revenue | $447,022,000.00 | ★ $20,245,000,000.00 |
| Revenue This Year | $43.95 | $2.58 |
| Revenue Next Year | $130.35 | $3.33 |
| P/E Ratio | ★ N/A | $81.62 |
| Revenue Growth | ★ 30.34 | N/A |
| 52 Week Low | $60.40 | $85.12 |
| 52 Week High | $212.75 | $127.33 |
| Indicator | INSM | DEO |
|---|---|---|
| Relative Strength Index (RSI) | 39.45 | 44.46 |
| Support Level | $173.24 | $85.48 |
| Resistance Level | $179.44 | $86.94 |
| Average True Range (ATR) | 5.92 | 1.18 |
| MACD | -1.75 | 0.09 |
| Stochastic Oscillator | 32.48 | 39.02 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Formed in 1997 through the merger of Grand Metropolitan and Guinness, Diageo is the largest distiller globally by sales. Diageo acquired some of the Seagram assets in 2001, which gave it brands such as Captain Morgan rum and Crown Royal Canadian whisky. Since then, mergers and acquisitions have mostly been bolt-on in nature, plugging gaps in the company's product and geographic portfolio. The firm has also shed noncore brands over the years, including the majority of its wine assets in 2015.